BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17490732)

  • 21. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
    McIntosh MW; Drescher C; Karlan B; Scholler N; Urban N; Hellstrom KE; Hellstrom I
    Gynecol Oncol; 2004 Oct; 95(1):9-15. PubMed ID: 15385104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
    Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
    Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
    McIntosh MW; Liu Y; Drescher C; Urban N; Diamandis EP
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4422-8. PubMed ID: 17671125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer.
    Yabushita H; Masuda T; Ogawa A; Noguchi M; Ishihara M
    Gynecol Oncol; 1988 Jan; 29(1):66-75. PubMed ID: 3422208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer.
    Xu X; Xiao Y; Hong B; Hao B; Qian Y
    Cancer Biomark; 2019; 25(3):251-257. PubMed ID: 31282407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
    Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R
    Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.
    Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS
    Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
    Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H; Duranyildiz D; Tas F; Yasasever V
    Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of serum biomarkers for detection of early stage ovarian cancer.
    Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
    Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
    Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
    Fauci JM; Straughn JM; Ferrone S; Buchsbaum DJ
    Gynecol Oncol; 2012 Nov; 127(2):420-5. PubMed ID: 22910694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
    Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
    Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
    Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
    Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors.
    Edfeldt K; Daskalakis K; Bäcklin C; Norlén O; Tiensuu Janson E; Westin G; Hellman P; Stålberg P
    Neuroendocrinology; 2017; 105(2):170-181. PubMed ID: 27829249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    Biomarkers; 2014 Nov; 19(7):604-10. PubMed ID: 25174623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
    Oikonomopoulou K; Li L; Zheng Y; Simon I; Wolfert RL; Valik D; Nekulova M; Simickova M; Frgala T; Diamandis EP
    Br J Cancer; 2008 Oct; 99(7):1103-13. PubMed ID: 18766180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.